

# iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune-411001

Email: cscovidh@gmail.com | Website: www.covidhtechnologies.com | Tel: +91 83290 12053

Date: June 11, 2026

To,

**The Chief General Manager,**

**Listing Operations Department,**

**BSE Limited,**

20th Floor, P.J. Towers, Dalal Street,

Mumbai – 400 001.

**BSE Scrip Code:** 534920      **ISIN:** INE899M01020

Dear Sir / Ma'am,

**Sub: Outcome of the Board Meeting of iSERA Lifesciences Limited (formerly known as Covidh Technologies Limited) held on Wednesday, June 11, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of iSERA Lifesciences Limited (formerly known as "Covidh Technologies Limited") was held on Wednesday, June 11, 2026. The following businesses were transacted at the aforesaid Board Meeting:

**Item No. 1: Intimation of Change in Name pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015**

The Board took note of BSE Notice No. 20260610-35 dated June 10, 2026, issued by BSE Limited, informing trading members of the Exchange about the change in name of the Company from "Covidh Technologies Limited" to "iSERA Lifesciences Limited" and the consequent change in Scrip ID from "COVIDH" to "ISERA" on the BOLT Plus System with effect from June 16, 2026.

**Item No. 2: Taking note of BSE Advisory (Ref. No. DCS/NC/TS/WL/015/2026-2027) dated June 10, 2026**

The Board took note of the Advisory Letter bearing Ref. No. DCS/NC/TS/WL/015/2026-2027 dated June 10, 2026, received from BSE Limited, advising the Company regarding non-compliance with Regulation 45(1) & (3) of the SEBI (LODR) Regulations, 2015 in connection with the name change application.

The Board noted the corrective steps already taken by the Company, including the submission of the Ratification Letter dated May 05, 2026 to BSE Limited, wherein the Company had undertaken to place the matter before the shareholders for ratification at the upcoming General Meeting. The Board further noted that the Revised PCA Certificate confirming compliance with Regulation 45(1)(c) shall be obtained upon completion of the preferential allotment / acquisition process (being subject to the receipt of in-principle approval from BSE Limited and completion of the preferential allotment of equity shares to the shareholders of iSERA Biological Limited), and shall thereafter be placed before the shareholders for ratification at the upcoming General Meeting.

The Board directed the Management to exercise due caution and diligence in all future regulatory compliance matters to avoid recurrence of such lapses.

**Item No. 3: Adoption of New Corporate Logo of iSERA Lifesciences Limited**

The Board has approved the adoption of a new corporate logo of the Company with effect from **June 11, 2026**. The existing and new logos are as under:

Existing Logo

New Logo

# iSERA LIFESCIENCES LIMITED

(Formerly known as Covid Technologies Limited)

CIN: L72200PN1993PLC252720

Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune-411001

Email: [cscovidh@gmail.com](mailto:cscovidh@gmail.com) | Website: [www.covidhtechnologies.com](http://www.covidhtechnologies.com) | Tel: +91 83290 12053

---



The new logo reflects the Company's new identity and proposed strategic direction towards the life sciences, pharmaceutical, biotechnology and allied healthcare sectors, consistent with its new name "iSERA Lifesciences Limited". The Company confirms that the adoption of the new logo is consequent upon and consistent with the change of name of the Company and does not, by itself, constitute a change in the nature of business of the Company. The Company's business transition towards the life sciences sector is a matter already disclosed to the Exchange and is subject to the ongoing preferential allotment / acquisition process as intimated separately.

This is for your information and records.

Kindly take the above on record.

Thanking you.

Yours faithfully,

**For iSERA Lifesciences Limited**

*(Formerly known as Covidh Technologies Limited)*

**Deepakshi**

Company Secretary & Compliance Officer

Membership No.: A76335

Email: [cscovidh@gmail.com](mailto:cscovidh@gmail.com)